Drug safety hearing
This article was originally published in The Tan Sheet
Executive Summary
"To what extent do CDER's patient-focused communication tools provide useful information for people with low health literacy skills," is one question FDA's Center for Drug Evaluation & Research will address at a public hearing scheduled for Dec. 7-8. The center currently is seeking comment on six questions concerning CDER's ability to communicate drug safety information. The purpose of the hearing is to "obtain public input on CDER's current risk communication tools, identify stakeholders for collaboration and implementation of additional tools, and obtain greater understanding of the strengths and weaknesses of CDER's existing risk communication." Comments are due by Nov. 7...